Oncolytics Biotech Dividends and Buybacks
Dividend criteria checks 0/6
Oncolytics Biotech does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-3.6%
Buyback Yield
Total Shareholder Yield | -3.6% |
Future Dividend Yield | n/a |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Feb 23Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Nov 10We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Jul 07Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Mar 24Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?
Dec 09We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate
Aug 25Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
May 12We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Dec 02We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Aug 05Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth
Apr 15We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Dec 31Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ONC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ONC's dividend payments have been increasing.
Dividend Yield vs Market
Oncolytics Biotech Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (ONC) | n/a |
Market Bottom 25% (CA) | 1.8% |
Market Top 25% (CA) | 6.3% |
Industry Average (Biotechs) | 2.4% |
Analyst forecast (ONC) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate ONC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ONC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ONC's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ONC has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/17 05:21 |
End of Day Share Price | 2024/12/17 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oncolytics Biotech Inc. is covered by 24 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Douglas Loe | Byron Capital Markets |
John Newman | Canaccord Genuity |
Douglas Loe | Cantor Fitzgerald Canada Corporation |